Mainz Biomed B.V. (MYNZ)

Market Cap	7.42M
Revenue (ttm)	895,479
Net Income (ttm)	-26.30M
Shares Out	21.89M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	562,753
Open	0.370
Previous Close	0.345
Day's Range	0.321 - 0.397
52-Week Range	0.315 - 5.010
Beta	0.30
Analysts	Buy
Price Target	3.00 (+784.96%)
Earnings Date	Aug 13, 2024

About MYNZ

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: MYNZ

Financial Performance

In 2023, MYNZ's revenue was $895,479, an increase of 69.00% compared to the previous year's $529,877. Losses were -$26.30 million, -0.35% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 784.96% from the latest price.

Price Target

$3.0

(784.96% upside)

Analyst Consensus: Buy